Claims for Patent: 6,872,397
✉ Email this page to a colleague
Summary for Patent: 6,872,397
Title: | Method for treating neuromuscular disorders and conditions with botulinum toxin types A and B |
Abstract: | A method of treating a patient suffering from a disease, disorder or condition includes the administration to the patient of a therapeutically effective amount of botulinum toxin of a selected serotype until the patient experiences loss of clinical response to the administered botulinum toxin and thereafter administering to the patient a therapeutically effective amount of another botulinum toxin of a different serotype. |
Inventor(s): | Aoki; K. Roger (Laguna Hills, CA), Grayston; Michael W. (Irvine, CA), Carlson; Steven R. (Laguna Nigel, CA), Leon; Judith M. (Laguna Niguel, CA) |
Assignee: | Allergan, Inc. (Irvine, CA) |
Application Number: | 09/812,113 |
Patent Claims: | 1. A method of treating a patient suffering from a dystonial the method comprising intramuscular or subcutaneous administration to the patient of up to 1,000 units of a
botulinum toxin type A per patient treatment session until the patient experiences loss of clinical response to the administered botulinum toxin type A, as determined by a failure of the administered botulinum toxin type A to achieve a marked reduction
of or to substantially alleviate a symptom of the dystonia, and thereafter administering to the patient at least about 80 units of a botulinum toxin type B to thereby again achieve a marked reduction or a substantial alleviation of a symptom of the
dystonia.
2. The method of claim 1, wherein the dystonia is cervical dystonia. 3. A method of treating cervical dystonia in a patient, the method comprising intramuscular or subcutaneous administration to a patient with dystonia of up to 1,000 units of a botulinum toxin type A per patient treatment session until th patient experiences loss of clinical response to the administered botulinum toxin type A, as determined by a failure of the administered botulinum toxin type A to achieve a marked reduction of a symptom of the cervical dystonia, and thereafter administering to the patient at least about 80 units of a botulinum toxin type B. 4. The method of claim 3, wherein treating the cervical dystonia reduces the severity of an abnormal head position symptom of the cervical dystonia. 5. The method of claim 3, wherein treating the cervical dystonia reduces a neck pain associated with the cervical dystonia. |
Details for Patent 6,872,397
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Solstice Neurosciences, Llc | MYOBLOC | rimabotulinumtoxinb | Injection | 103846 | December 08, 2000 | ⤷ Subscribe | 2013-06-10 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 6,872,397
Country | Patent Number | Estimated Expiration |
---|---|---|
World Intellectual Property Organization (WIPO) | 9428922 | ⤷ Subscribe |
United States of America | 2005129716 | ⤷ Subscribe |
United States of America | 2002010138 | ⤷ Subscribe |
>Country | >Patent Number | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.